Ultra-LEAF™ Purified anti-human IL-22RA2 (IL-22BP) Antibody, IL-22RA2, W21014D,BioLegend,639353

IL-22BP is a soluble class 2 cytokine receptor family member (CRF2) without transmembrane and cytosolic domains.  IL-22BP binds to IL-22 and does not bind to other members of the IL-10 family. IL-22 signals through the mechanism that involves the sequential binding of IL-22 to interleukin-22 receptor 1 (IL-22R1), and of this dimer to interleukin-10 receptor 2 (IL-10R2) extracellular domain.  IL-22R1 expression is restricted to epithelial cells, hepatocytes, and acinar cells of the pancreas, whereas IL-10Rβ1 expression is ubiquitous. IL-22BP prevents the binding of IL-22 to the membrane bound IL-22R1. IL-22 has high affinity binding for IL-22BP, and it is 20- to 1000-fold higher compared to its binding to the membrane bound IL-22R1. IL-22BP inhibits IL-22 biological effects in vitro and in vivo and is constitutively expressed in secondary lymphoid organs, breast, and epithelial tissues such as gut, lung, and skin.IL-22BP plays a key role in controlling tumorigenesis and epithelial cell proliferation in the colon. High expression of IL-22BP has been detected in gastric adenoma tissues. In addition, non-affected skin of psoriasis patients shows lower expression of IL-22BP than skin of healthy controls; this decrease in IL-22BP exacerbates psoriatic skin inflammation.